These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 33090294)

  • 1. Cost-Effectiveness of Evolocumab Therapy for Myocardial Infarction: The Chinese Healthcare Perspective.
    Liang Z; Chen Q; Yang F; Yan X; Zhang X; Chen X; Fang F; Zhao Q
    Cardiovasc Drugs Ther; 2021 Aug; 35(4):775-785. PubMed ID: 33090294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease.
    Fonarow GC; Keech AC; Pedersen TR; Giugliano RP; Sever PS; Lindgren P; van Hout B; Villa G; Qian Y; Somaratne R; Sabatine MS
    JAMA Cardiol; 2017 Oct; 2(10):1069-1078. PubMed ID: 28832867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.
    Kazi DS; Moran AE; Coxson PG; Penko J; Ollendorf DA; Pearson SD; Tice JA; Guzman D; Bibbins-Domingo K
    JAMA; 2016 Aug; 316(7):743-53. PubMed ID: 27533159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of Evolocumab in Patients With High Cardiovascular Risk in Spain.
    Villa G; Lothgren M; Kutikova L; Lindgren P; Gandra SR; Fonarow GC; Sorio F; Masana L; Bayes-Genis A; Hout BV
    Clin Ther; 2017 Apr; 39(4):771-786.e3. PubMed ID: 28366593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Evolocumab and Ezetimibe, Both Combined with Statin Therapy, for Patients with Recent Acute Coronary Syndrome: A Cost-Effectiveness Analysis from the Chinese Healthcare Perspective.
    Xi X; Wang X; Xie W; Jia Y; Sanchez SZ; Martinez L; Zhao Q
    Cardiovasc Drugs Ther; 2023 Oct; 37(5):905-916. PubMed ID: 35467312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab in patients with a history of myocardial infarction in Sweden.
    Landmesser U; Lindgren P; Hagström E; van Hout B; Villa G; Pemberton-Ross P; Arellano J; Svensson ME; Sibartie M; Fonarow GC
    Eur Heart J Qual Care Clin Outcomes; 2022 Jan; 8(1):31-38. PubMed ID: 33063111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-Effectiveness of Alirocumab for the Secondary Prevention of Cardiovascular Events after Myocardial Infarction in the Chinese Setting.
    Liang Z; Chen Q; Wei R; Ma C; Zhang X; Chen X; Fang F; Zhao Q
    Front Pharmacol; 2021; 12():648244. PubMed ID: 33935749
    [No Abstract]   [Full Text] [Related]  

  • 8. Cost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States.
    Gandra SR; Villa G; Fonarow GC; Lothgren M; Lindgren P; Somaratne R; van Hout B
    Clin Cardiol; 2016 Jun; 39(6):313-20. PubMed ID: 27092712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-Effectiveness of Evolocumab in Adult Patients with Atherosclerotic Cardiovascular Disease from Chinese Healthcare Perspective.
    Xie W; Song Y; Qin X; Jin P
    Adv Ther; 2023 Feb; 40(2):489-503. PubMed ID: 36371480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methodology and results of cost-effectiveness of LDL-C lowering with evolocumab in patients with acute myocardial infarction in China.
    Wan Y; Liu J; Zhan X; Zhang Y; You R
    Cost Eff Resour Alloc; 2023 Dec; 21(1):93. PubMed ID: 38041072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inclisiran as Adjunct Lipid-Lowering Therapy for Patients with Cardiovascular Disease: A Cost-Effectiveness Analysis.
    Kam N; Perera K; Zomer E; Liew D; Ademi Z
    Pharmacoeconomics; 2020 Sep; 38(9):1007-1020. PubMed ID: 32789593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy.
    Michaeli DT; Michaeli JC; Boch T; Michaeli T
    Clin Drug Investig; 2022 Aug; 42(8):643-656. PubMed ID: 35819632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cost-effectiveness of PCSK9 inhibitors - The Australian healthcare perspective.
    Kumar R; Tonkin A; Liew D; Zomer E
    Int J Cardiol; 2018 Sep; 267():183-187. PubMed ID: 29731350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: Analysis From FOURIER.
    Sabatine MS; De Ferrari GM; Giugliano RP; Huber K; Lewis BS; Ferreira J; Kuder JF; Murphy SA; Wiviott SD; Kurtz CE; Honarpour N; Keech AC; Sever PS; Pedersen TR
    Circulation; 2018 Aug; 138(8):756-766. PubMed ID: 29626068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Updated Cost-effectiveness Analysis of Evolocumab in Patients With Very High-risk Atherosclerotic Cardiovascular Disease.
    Fonarow GC; van Hout B; Villa G; Arellano J; Lindgren P
    JAMA Cardiol; 2019 Jul; 4(7):691-695. PubMed ID: 31166576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia.
    Santos RD; Ruzza A; Hovingh GK; Wiegman A; Mach F; Kurtz CE; Hamer A; Bridges I; Bartuli A; Bergeron J; Szamosi T; Santra S; Stefanutti C; Descamps OS; Greber-Platzer S; Luirink I; Kastelein JJP; Gaudet D;
    N Engl J Med; 2020 Oct; 383(14):1317-1327. PubMed ID: 32865373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-Effectiveness Analysis of Evolocumab in Adult Patients with Atherosclerotic Cardiovascular Disease in Canada.
    Grégoire J; Champsi S; Jobin M; Martinez L; Urbich M; Rogoza RM
    Adv Ther; 2022 Jul; 39(7):3262-3279. PubMed ID: 35604523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers: Insights Derived From the FOURIER Trial.
    Arrieta A; Hong JC; Khera R; Virani SS; Krumholz HM; Nasir K
    JAMA Cardiol; 2017 Dec; 2(12):1369-1374. PubMed ID: 29049467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of PCSK9 inhibition in addition to standard lipid-lowering therapy in patients at high risk for vascular disease.
    Stam-Slob MC; van der Graaf Y; de Boer A; Greving JP; Visseren FLJ
    Int J Cardiol; 2018 Feb; 253():148-154. PubMed ID: 29306457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modelling the cost-effectiveness of PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting.
    Korman M; Wisløff T
    Eur Heart J Cardiovasc Pharmacother; 2018 Jan; 4(1):15-22. PubMed ID: 28444187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.